The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms, randomized trials, and microbiome consequences.
PubMed 28592442 · doi:10.1136/gutjnl-2017-313750
What was done
This narrative review synthesized recent mechanistic, clinical, and microbiological research on the low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet in irritable bowel syndrome (IBS). It reviewed physiological mechanisms assessed by magnetic resonance imaging (MRI) and summarized efficacy findings from clinical trials alongside impacts on the gut microbiome.
What was found
The authors noted that MRI studies demonstrate short-chain fermentable carbohydrates increase small intestinal water volume and colonic gas production, provoking symptoms in patients with visceral hypersensitivity. At least 10 randomized controlled or comparative trials demonstrated that a low FODMAP diet achieves a clinical response in 50% to 80% of IBS patients, specifically improving bloating, flatulence, diarrhea, and global symptoms. However, studies also showed profound alterations in the gut microbiota and metabolome, with unknown duration and clinical relevance.
Why it matters
This review outlines the physiological basis and randomized trial support for using a low FODMAP diet as a clinical intervention for IBS. It also highlights the critical need to evaluate whether diet-induced shifts in the microbiome and metabolome pose long-term clinical risks.
Limits
The paper is a narrative review without systematic search protocols, risk-of-bias grading, or quantitative meta-analysis. Long-term adherence, clinical durability, and the physiological relevance of observed microbiome changes remain undetermined.
Cited by
- supports Consuming excess fiber can cause fermentation imbalances and excessive gas production in individuals with gut dysbiosis.